While the POLE mutation is associated with an increased tumor burden and various other genetic deficiencies, the increased tumor immunogenicity enhances responsiveness to immune checkpoint inhibitors and offers a positive predictive biomarker for IO use. Here, POLE is linked to neoplasm.